• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Over 700 employees transfered from Almirall to AstraZeneca as part of respiratory drug deal

As AstraZeneca completes the acquisition of Almirall's respiratory drug franchise, which was first announced in July 2014, Almirall says that 719 employees will transfer to AstraZeneca. The deal includes the inhalation R&D company Almirall Sofotec as well as a number of inhalers, including the Eklira/Bretaris/Tudorza aclidinium DPI, the Duaklir Genuair … [Read more...] about Over 700 employees transfered from Almirall to AstraZeneca as part of respiratory drug deal

Sales of Zomig nasal spray increase 54%

Impax Laboratories has reported a 19.1% increase in total revenues for the quarter ended September 30, 2014 compared to the third quarter of the prior year. The company attributes a portion of the increase in revenues to a 54% increase in sales of Zomig zolmitriptan nasal spray, which it markets in the US for the treatment of migraine. Impax acquired the rights to … [Read more...] about Sales of Zomig nasal spray increase 54%

BMS makes deal for inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis

Bristol-Myers Squibb could pay a total of up to $444 million to acquire Galecto Biotech and its TD139 inhaled galectin-3 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF), plus potential milestones. The newly announced deal includes an option to acquire the company that must be exercised no later than 60 days after completion of a Phase 1b trial of … [Read more...] about BMS makes deal for inhaled galectin-3 inhibitor for idiopathic pulmonary fibrosis

Ferrer to become Alexza Pharmaceuticals’ largest shareholder

Grupo Ferrer Internacional, which markets Alexza Pharmaceuticals' Adasuve inhaled loxapine in the EU, Latin America, and the CIS countries, will acquire 2 million shares of Alexza common stock at $4 per share, the companies have announced. The amendment to the two companies' agreement on Adasuve will make Ferrer the largest shareholder in Alexza and includes … [Read more...] about Ferrer to become Alexza Pharmaceuticals’ largest shareholder

Ferring reacquires rights to desmopressin nasal spray

Ferring Pharmaceuticals has announced that it has reacquired desmopressin acetate (DDAVP), which is approved as a nasal spray and a number of other formulations, from Sanofi. Ferring originally developed desmopressin, which is a synthetic form of vasopressin and is used to reduce frequent urination among other conditions. In 2007, the FDA announced that the … [Read more...] about Ferring reacquires rights to desmopressin nasal spray

Retrophin divests Syntocinon nasal spray to Turing Pharmaceuticals

Retrophin has announced that Turing Pharmaceuticals will pay $3 million up front for three of Retrophin's products, including Syntocinon oxytocin nasal spray and ketamine. According to the company, the agreement includes the resignation of Retrophin founder Martin Shkreli. Shkreli's Twitter profile identifies him as the CEO of Turing Pharmaceuticals. The company … [Read more...] about Retrophin divests Syntocinon nasal spray to Turing Pharmaceuticals

Striverdi Respimat launched in the US

Boehringer Ingelheim has announced that the Striverdi Respimat olodaterol soft mist inhaler is now available in the United States. The FDA approved Striverdi Respimat for the treatment of COPD in July 2014. The company said that a savings program will be available, allowing most patients to get the inhaler free for a period of time. The card will provide the … [Read more...] about Striverdi Respimat launched in the US

Teva to focus on respiratory, CNS drug businesses

Teva Pharmaceutical has completed a strategic review of its core therapeutic areas and will focus its development efforts on central nervous system and respiratory drugs, the company has announced. According to the announcement, 14 drug development programs currently underway at Teva in other therapeutic areas will be divested or discontinued, with the $150-200 … [Read more...] about Teva to focus on respiratory, CNS drug businesses

Savara raises $10 million for AeroVanc development

Savara Pharmaceuticals has announced the completion of enrollment in a Phase 2 trial of its AeroVanc vancomycin DPI for the treatment of for the treatment of methicillin-resistant S. aureus (MRSA) lung infections in cystic fibrosis patients, as well as the closing of a $10 million bridge financing round for further development. In December 2013, AeroVanc received … [Read more...] about Savara raises $10 million for AeroVanc development

Retrophin replaces CEO

Retrophin has announced that Stephen Aselage will take over as interim CEO immediately, replacing company founder and CEO Martin Shkreli. According to reports, Shkreli was fired for "stock trading irregularities" and other rules violations. Aselage commented, "I am excited about the direction and future of Retrophin. We have three marketed products with a growing … [Read more...] about Retrophin replaces CEO

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • Page 104
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Intertek banner
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews